// App-Quantinova.ai

TPS621 : A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2negative hormone receptorpositive breast cancer and bone metastases.

Researchers

Presenter

  • Hope S. Rugo

Principal Investigators

  • Rui Li

  • Oana Petrenciuc

  • Amily Zhang

  • Robert E. Coleman

Medical Centers

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Pharmaceuticals Division of Bayer, Whippany, NJ

  • University of Sheffield, Weston Park Hospital, Sheffield, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Bone metastases

  • Breast cancer

  • Solid malignancies

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Alpharadin

  • Everolimus

  • Exemestane

  • Radium-223 Dichloride

  • Denosumab

  • Opiate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT02258451

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved